Abzena Grants Exclusive Commercial License to Orion for Groundbreaking Antibody Targeting High Clinical Need Cancer Abzena has partnered with Orion to provide an exclusive commercial license for one of its antibodies, enhancing Orion's oncology pipeline significantly.

Abzena Grants Exclusive Commercial License to Orion for Groundbreaking Antibody Targeting High Clinical Need Cancer #USA #San_Diego #Abzena #Antibody_Licensing #Orion_Pharmaceuticals